Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months
ISRN Immunology · 2013
DOI: 10.1155/2013/548312 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Immunology, 2013. Verfasst von E. I. Alexeeva und 10 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
The results of the retrospective study evaluating efficacy and safety of tocilizumab treatment in 75 patients with severe systemic-onset juvenile idiopathic arthritis refractory to standard immunosuppressive therapy are presented in the paper. Inactive disease was documented in 64% of patients after 6 months of treatment and in 73% of patients after 12 months. Adverse events manifested as mild and moderate infections as well as laboratory abnormalities: leukopenia, neutropenia, and elevated aminotransferase levels.
Zitieren
APA
Alexeeva, E. I., Baranov, A. A., Denisova, R. V., Valieva, S. I., Bzarova, T. M., Isaeva, K. B., Sleptsova, T. V., Mitenko, E. V., Taybulatov, N. I., Chistyakova, E. G., & Fetisova, A. N. (2013). Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months. ISRN Immunology. https://doi.org/10.1155/2013/548312
Vancouver
Alexeeva EI, Baranov AA, Denisova RV, Valieva SI, Bzarova TM, Isaeva KB, et al. Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months. ISRN Immunology. 2013. doi:10.1155/2013/548312
BibTeX
@article{Alexeeva2013,
author = {Alexeeva, E. I. and Baranov, A. A. and Denisova, R. V. and Valieva, S. I. and Bzarova, T. M. and Isaeva, K. B. and Sleptsova, T. V. and Mitenko, E. V. and Taybulatov, N. I. and Chistyakova, E. G. and Fetisova, A. N.},
title = {Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months},
journal = {ISRN Immunology},
year = {2013},
doi = {10.1155/2013/548312}
}
EUVIMED